Cargando…
Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant
Patients after autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) are at an increased risk of COVID-19-related morbidity and mortality, compounded by an immune system weakened by the underlying malignancy and prior treatments. Allogeneic transplantation, including stem cell and...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310198/ https://www.ncbi.nlm.nih.gov/pubmed/34358153 http://dx.doi.org/10.3390/vaccines9070737 |
_version_ | 1783728703027544064 |
---|---|
author | Atanackovic, Djordje Luetkens, Tim Avila, Stephanie V. Hardy, Nancy M. Lutfi, Forat Sanchez-Petitto, Gabriela Vander Mause, Erica Glynn, Nicole Mannuel, Heather D. Alkhaldi, Hanan Hankey, Kim Baddley, John Dahiya, Saurabh Rapoport, Aaron P. |
author_facet | Atanackovic, Djordje Luetkens, Tim Avila, Stephanie V. Hardy, Nancy M. Lutfi, Forat Sanchez-Petitto, Gabriela Vander Mause, Erica Glynn, Nicole Mannuel, Heather D. Alkhaldi, Hanan Hankey, Kim Baddley, John Dahiya, Saurabh Rapoport, Aaron P. |
author_sort | Atanackovic, Djordje |
collection | PubMed |
description | Patients after autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) are at an increased risk of COVID-19-related morbidity and mortality, compounded by an immune system weakened by the underlying malignancy and prior treatments. Allogeneic transplantation, including stem cell and solid organ transplants, requires intensive immunosuppressive prophylaxis, which may further undermine the development of a protective vaccine-induced anti-viral immunity. Herein, we report on short- and long-term antiviral immune responses in two peri-stem cell transplant recipients and a third patient who received a COVID-19 vaccination after kidney transplantation. Our data indicate that: (1) patients post-alloSCT may be able to mount an anti-COVID-19 immune response; however, a sufficient time interval between transplant and exposure may be of critical importance; (2) alloSCT recipients with preexisting anti-SARS-CoV-2 immunity are at risk for losing protective humoral immunity following transplantation, particularly if the stem-cell donor lacks antiviral immunity, e.g., vaccine-derived immunity; and (3) some post-transplant patients are completely unable to build an immune response to a COVID-19 vaccine, perhaps based on the prophylactic suppression of T cell immunity. |
format | Online Article Text |
id | pubmed-8310198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83101982021-07-25 Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant Atanackovic, Djordje Luetkens, Tim Avila, Stephanie V. Hardy, Nancy M. Lutfi, Forat Sanchez-Petitto, Gabriela Vander Mause, Erica Glynn, Nicole Mannuel, Heather D. Alkhaldi, Hanan Hankey, Kim Baddley, John Dahiya, Saurabh Rapoport, Aaron P. Vaccines (Basel) Case Report Patients after autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) are at an increased risk of COVID-19-related morbidity and mortality, compounded by an immune system weakened by the underlying malignancy and prior treatments. Allogeneic transplantation, including stem cell and solid organ transplants, requires intensive immunosuppressive prophylaxis, which may further undermine the development of a protective vaccine-induced anti-viral immunity. Herein, we report on short- and long-term antiviral immune responses in two peri-stem cell transplant recipients and a third patient who received a COVID-19 vaccination after kidney transplantation. Our data indicate that: (1) patients post-alloSCT may be able to mount an anti-COVID-19 immune response; however, a sufficient time interval between transplant and exposure may be of critical importance; (2) alloSCT recipients with preexisting anti-SARS-CoV-2 immunity are at risk for losing protective humoral immunity following transplantation, particularly if the stem-cell donor lacks antiviral immunity, e.g., vaccine-derived immunity; and (3) some post-transplant patients are completely unable to build an immune response to a COVID-19 vaccine, perhaps based on the prophylactic suppression of T cell immunity. MDPI 2021-07-03 /pmc/articles/PMC8310198/ /pubmed/34358153 http://dx.doi.org/10.3390/vaccines9070737 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Atanackovic, Djordje Luetkens, Tim Avila, Stephanie V. Hardy, Nancy M. Lutfi, Forat Sanchez-Petitto, Gabriela Vander Mause, Erica Glynn, Nicole Mannuel, Heather D. Alkhaldi, Hanan Hankey, Kim Baddley, John Dahiya, Saurabh Rapoport, Aaron P. Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant |
title | Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant |
title_full | Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant |
title_fullStr | Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant |
title_full_unstemmed | Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant |
title_short | Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant |
title_sort | anti-sars-cov-2 immune responses in patients receiving an allogeneic stem cell or organ transplant |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310198/ https://www.ncbi.nlm.nih.gov/pubmed/34358153 http://dx.doi.org/10.3390/vaccines9070737 |
work_keys_str_mv | AT atanackovicdjordje antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT luetkenstim antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT avilastephaniev antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT hardynancym antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT lutfiforat antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT sanchezpetittogabriela antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT vandermauseerica antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT glynnnicole antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT mannuelheatherd antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT alkhaldihanan antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT hankeykim antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT baddleyjohn antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT dahiyasaurabh antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant AT rapoportaaronp antisarscov2immuneresponsesinpatientsreceivinganallogeneicstemcellororgantransplant |